Therefore, further analyses are needed to clarify the role of the CTRB1-CTRB2 locus in pancreatic cancer risk, which could include pre-clinical assessment of CTRB1 and CTRB2 as potential anti-tumour agents as was previously conducted for pro-enzymes PRSS1 and Chymotrypsinogen A28. Here, PRSS1 is linked to pancreatic neoplasm.